Jonathan Aschoff
Stock Analyst at Roth Capital
(0.43)
# 4,200
Out of 5,122 analysts
38
Total ratings
24.32%
Success rate
-38.88%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Initiates: Buy | $57 | $23.31 | +144.53% | 1 | Nov 25, 2025 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.53 | +1,987.68% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $8.94 | +134.90% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $199,800 → $106,560 | $6.42 | +1,661,006.78% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.03 | +1,647.57% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $3.02 | +23,542.38% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $500 | $2.82 | +17,630.50% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $1,000 | $4.18 | +23,823.44% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $2.99 | +27,993.65% | 4 | Mar 28, 2024 | |
| HSDT Solana Company | Maintains: Buy | $3,750 → $18,000 | $2.22 | +810,710.81% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $13.13 | +128.48% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $3.99 | +4,912.53% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $6.12 | +128.76% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28,800 → $86,400 | $1.59 | +5,433,862.26% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.41 | +467.38% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.94 | +5,054.64% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.87 | +45,977.64% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $10.18 | +273.28% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.67 | +5,648.50% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.52 | +755.26% | 1 | Dec 19, 2019 |
Pelthos Therapeutics
Nov 25, 2025
Initiates: Buy
Price Target: $57
Current: $23.31
Upside: +144.53%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.53
Upside: +1,987.68%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $8.94
Upside: +134.90%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $199,800 → $106,560
Current: $6.42
Upside: +1,661,006.78%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.03
Upside: +1,647.57%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $3.02
Upside: +23,542.38%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $500
Current: $2.82
Upside: +17,630.50%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $1,000
Current: $4.18
Upside: +23,823.44%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $2.99
Upside: +27,993.65%
Solana Company
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $2.22
Upside: +810,710.81%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $13.13
Upside: +128.48%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $3.99
Upside: +4,912.53%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $6.12
Upside: +128.76%
Feb 14, 2023
Maintains: Buy
Price Target: $28,800 → $86,400
Current: $1.59
Upside: +5,433,862.26%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.41
Upside: +467.38%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $1.94
Upside: +5,054.64%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.87
Upside: +45,977.64%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $10.18
Upside: +273.28%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.67
Upside: +5,648.50%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.52
Upside: +755.26%